At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

Clinical Trials & Research

Ph1/2 BDC-1001 +/- Pembro HER2 Solids

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced HER2-Expressing Solid Tumors (BBI-20201001)

Disease Types: Solid Tumors,&nbs

Available at: {clinical_trial_location backspace="7"}Ph1/2 BDC-1001 +/- Pembro HER2 Solids, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}